Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the “Company”) has resolved to increase the Company’s share capital, related to the exercise of options, by NOK 13,070 through the issuance of 130,700 new shares, each with a par value of NOK 0.10. The resolution is based on an authorisation to increase the share capital granted by the Company’s general meeting on 21 April 2022. Following the option exercise, 2,138,885 options are outstanding.
The new shares are issued to employees of the Company in connection with the Company’s employee incentive program. The new shares are issued at a subscription price of NOK 31.25 per share for 127,592 shares and NOK 39.15 per share for 3,108 shares.
Following registration of the share capital increase with the Norwegian Register of Business Enterprises, the Company will have a share capital of NOK 3,439,646.10, divided into 34,396,461 shares, each with a par value of NOK 0.10.
For further information, please contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Phone: +47 480 96 355
Carlos de Sousa, CEO
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Phone: +47 482 48632